CLL210 logo

CLL210

Phase II trial of ofatumumab, dexamethasone and lenalidomide for high-risk CLL (NCRI CLL210)

CLL210

Phase II trial of ofatumumab, dexamethasone and lenalidomide for high-risk CLL (NCRI CLL210)
Funding Celgene
Portfolio Cancer
Interventions Medicine
Randomised Yes
Status Closed
Start Date 23-Jan-2012

CLL210 is a study that recruited patients with high risk CLL, defined as having 17p deletion or early treatment of fludarabin treatment. Patients who achieved a favourable response to treatment, i.e. no severe severe toxicity, they were randomised to either receive receive maintenance or not prior to being followed up for survival. The main rationale of the study is to see how well the inclusion of maintenance therapy is in extending remission of patients, whilst at the same time assessing the long term side effects associated with combination therapy.

Publications

  • Formative: Andrew R Pettitt, Fotios Polydoros, James Dodd, Melanie Oates, Ke Lin, Nagesh Kalakonda, Helen McCarthy, Adrian Bloor, Anna Schuh, Andrew Duncombe, Claire Dearden, Christopher Fegan, Ben Kennedy, Christina Yap, Sarah E Coupland, Peter HillmenEHA Library. Pettitt A. Jun 9, 2016; 134694; PB1794 OVerall study: Peer review under way